<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04267536</url>
  </required_header>
  <id_info>
    <org_study_id>P20-078</org_study_id>
    <nct_id>NCT04267536</nct_id>
  </id_info>
  <brief_title>An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid Arthritis</brief_title>
  <acronym>UPWARDS</acronym>
  <official_title>UPwArds - Post Marketing Observational Study to Evaluate the Impact of CRP-Level on the Real World Effectiveness of UPadacitinib When Used in MonotherApy or in Combination With MTX in Patients With RheumatoiD ArthritiS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling
      and loss of joint function. RA can reduce the ability to perform everyday tasks. This study
      assesses whether C-reactive protein (CRP)-level has an impact on achieving remission with
      upadacitinib when used alone or in combination with methotrexate (MTX). This study will also
      assess the reduction in pain, morning stiffness, fatigue, functionality, health status and
      impact of RA.

      CRP is an indicator of inflammation and often used for disease activity monitoring during RA
      treatment. Upadacitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of
      adults with moderately to severely active RA who have had an inadequate response or
      intolerance to methotrexate. This study has two groups - upadacitinib monotherapy and
      combination. Adult participants with moderate to severe RA will be enrolled. Around 500
      participants will be enrolled in the study in multiple sites within Germany.

      Participants will receive upadacitinib alone or in combination with MTX per their physicians'
      usual prescription. Individual data will be collected for 12 months.

      No additional study-related tests will be conducted during the routine physician visits. Only
      data which are routinely collected during a regular visit will be utilized for this study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Remission</measure>
    <time_frame>6 Months</time_frame>
    <description>Remission is defined as clinical disease activity index (CDAI) &lt;=2.8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Remission</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>Remission is defined as the disease activity score at 28 joints (DAS28)-C-Reactive protein (CRP)&lt;2.6, DAS28- erythrocyte sedimentation rate (ESR)&lt;2.6, simplified disease activity index (SDAI)&lt;=3.3, CDAI&lt;=2.8, Boolean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Low Disease Activity (LDA)</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>LDA is defined as DAS28-CRP&lt;3.2, DAS28-ESR&lt;3.2, SDAI &lt;=11, CDAI&lt;=10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CDAI</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>The CDAI is a validated measure of RA disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global health assessed by the participant on a visual analogue scale (VAS) from 0 to 10 (cm), and global health assessed by an investigator on a visual analogue scale from 0 to 10 (cm) were included in the CDAI score. Scores on the CDAI range from 0 (lowest disease activity) to 76 (highest disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SDAI</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>The SDAI is a validated measure of RA disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global disease activity assessed by the participant on a visual analogue scale from 0 to 10 (cm) , global disease activity assessed by an investigator on a visual analogue scale from 0 to 10 (cm), and serum levels of C-reactive protein (mg/dL) were included in the SDAI score. Scores on the SDAI range from 0 (lowest disease activity) to 86 (highest disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-CRP</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>The Disease Activity Score (DAS) 28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 (lowest disease activity) to 10 (highest disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in DAS28-ESR</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>The Disease Activity Score (DAS) 28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 (lowest disease activity) to 10 (highest disease activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Pain Reduction (Improvement by 30 %)</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>Improvement in pain reduction is assessed by numeric rating scale (NRS). The NRS of Pain sheet will be filled out in the office by participants at the designated visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Pain Reduction (Improvement by 50 %)</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>Improvement in pain reduction is assessed by numeric rating scale (NRS). The NRS of Pain sheet will be filled out in the office by participants at the designated visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Pain Reduction (Improvement by 70 %)</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>Improvement in pain reduction is assessed by numeric rating scale (NRS). The NRS of Pain sheet will be filled out in the office by participants at the designated visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Pain</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>The NRS of Pain sheet will be filled out in the office by participants at the designated visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Fatigue Reduction (Improvement by 30 %)</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>Improvement in fatigue reduction is assessed by numeric rating scale (NRS). The NRS of fatigue sheet will be filled out in the office by participants at the designated visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Fatigue Reduction (Improvement by 50 %)</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>Improvement in fatigue reduction is assessed by numeric rating scale (NRS). The NRS of fatigue sheet will be filled out in the office by participants at the designated visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Fatigue Reduction (Improvement by 70 %)</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>Improvement in fatigue reduction is assessed by numeric rating scale (NRS). The NRS of fatigue sheet will be filled out in the office by participants at the designated visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Fatigue</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>Change in Fatigue is assessed by numeric rating scale (NRS). The NRS of fatigue sheet will be filled out in the office by participants at the designated visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID)</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>RAID is a tool for assessment of disease activity purely based on a patient questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving RAID &lt;= 3</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>RAID is a tool for assessment of disease activity purely based on a patient questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving RAID &gt; 3 and &lt;=4</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>RAID is a tool for assessment of disease activity purely based on a patient questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving RAID &gt; 4 and &lt;=6</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>RAID is a tool for assessment of disease activity purely based on a patient questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving RAID &gt; 6</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>RAID is a tool for assessment of disease activity purely based on a patient questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Stiffness Severity</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing &quot;not severe&quot; and 10 &quot;very severe&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Stiffness Duration</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>The duration of morning stiffness was reported by participants as the average daily length during the past week in minutes (from time of awaking to time of maximal improvement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functionality (FFbH)</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>A self-administered patient questionnaire used to assess patient function based on 18 questions. The numerically coded responses to the questions are added to provide a total patient score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>The PHQ-9 is a 9-item questionnaire for assessing the severity of depression. Each question is answered on a scale from 0 (not at all) to 3 (nearly every day). The total score ranges from 0 to 27, where higher scores indicate more severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Minimal Clinically Important Difference (MCID) in PHQ-9</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>MCID is defined as the at least 5 points difference from baseline in PHQ-9. The PHQ-9 is a 9-item questionnaire for assessing the severity of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Low Disease Activity (LDA) or Remission Without Actual Concomitant MTX</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>LDA is defined as DAS28 &lt; 3.2, CDAI&lt;=10, SDAI &lt;11. Remission is defined as DAS28&lt;2.6, CDAI&lt;=2.8; Boolean Remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With LDA or Remission With Actual Concomitant MTX</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>LDA is defined as DAS28 &lt; 3.2, CDAI&lt;=10, SDAI &lt;11. Remission is defined as DAS28&lt;2.6, CDAI&lt;=2.8; Boolean Remission.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Participants treated with upadacitinib monotherapy</arm_group_label>
    <description>Participants will receive upadacitinib for 12 months as prescribed by the physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants treated with upadacitinib in combination with MTX</arm_group_label>
    <description>Participants will receive upadacitinib in combination with MTX as prescribed by the physician for 12 months</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult Participants with moderate to severe rheumatoid arthritis (RA)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of moderate to severe active rheumatoid arthritis (RA) upon judgment of the
             treating physician.

          -  Swollen Joint Count (SJC) &gt;= 3 of 28 joints of the Disease Activity Score (DAS)28.

          -  Measurement of C-Reactive Protein (CRP)-level at Baseline (BL) or &lt;= 4 weeks prior to
             BL at a timepoint when the Prednisolone equivalent dose of Glucocorticoid treatment
             was &lt;= 10 mg/day for at least 7 days.

          -  Upadacitinib treatment is indicated as per local Summary of Product characteristics
             (SmPC).

          -  Decision on the treatment with Upadacitinib was made prior to any decision to approach
             the patient to participate in this study.

        Exclusion Criteria:

          -  Participants who cannot be treated with Upadacitinib according to the local
             Upadacitinib SmPC.

          -  Prior treatment with Upadacitinib.

          -  Treatment with Sarilumab or Tocilizumab within the last 8 weeks before the CRP level
             for inclusion was measured.

          -  Participants currently participating in interventional research.

          -  Participants who are unwilling or unable to complete the patient reported
             questionnaires.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Praxis Dr. Haas, Tuebingen, DE /ID# 218423</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Rinaldi /ID# 218424</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Kellerer/Kellerer/Krüger /ID# 218428</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>81541</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumahaus Studien GbR, Potsdam, DE /ID# 218430</name>
      <address>
        <city>Potsdam</city>
        <state>Brandenburg</state>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Lüthke /ID# 218900</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01097</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kupka &amp; Kupka, Altenburg, DE /ID# 218413</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marycz, Amberg, DE /ID# 220808</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis am Webereck /ID# 218712</name>
      <address>
        <city>Augsburg</city>
        <zip>86157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schmitt-Haendle /ID# 218540</name>
      <address>
        <city>Bayreuth</city>
        <zip>95444</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bozorg-Doagoo, Berlin, DE /ID# 218431</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Silke Zinke /ID# 218433</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisterhues, Braunschweig, DE /ID# 218532</name>
      <address>
        <city>Braunschweig</city>
        <zip>38100</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ Agilomed /ID# 218538</name>
      <address>
        <city>Chemnitz</city>
        <zip>D-09130</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dres. Schuh /ID# 218541</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumatologisches MVZ Dresden /ID# 218411</name>
      <address>
        <city>Dresden</city>
        <zip>01109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Strothmeyer &amp; Scheulen /ID# 218426</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40211</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dilltal /ID# 218427</name>
      <address>
        <city>Ehringshausen</city>
        <zip>35630</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dres. Waehrisch/Flaxenberg /ID# 218711</name>
      <address>
        <city>Essen</city>
        <zip>45326</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michael Mueller, Freiberg, DE /ID# 218414</name>
      <address>
        <city>Freiberg</city>
        <zip>09599</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Liebhaber /ID# 218899</name>
      <address>
        <city>Halle</city>
        <zip>06128</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aries, Hamburg, DE /ID# 220804</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stille, Hanover, DE /ID# 218429</name>
      <address>
        <city>Hannover</city>
        <zip>30161</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis K. Pagel /ID# 218714</name>
      <address>
        <city>Hoppegarten</city>
        <zip>15366</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamann &amp; Teich &amp; Boche,Leipzig /ID# 218531</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schwarze/Haeder, Leipzig, DE /ID# 218412</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aurich &amp; Sieburg, Magdeburg /ID# 220811</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harmuth, Marktredwitz, DE /ID# 218715</name>
      <address>
        <city>Marktredwitz</city>
        <zip>95615</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prof-med-stud.de /ID# 218534</name>
      <address>
        <city>Munich</city>
        <zip>80935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med Thilo Klopsch /ID# 218535</name>
      <address>
        <city>Neubrandenburg</city>
        <zip>17033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wagener &amp; Hein, Nienburg, DE /ID# 218716</name>
      <address>
        <city>Nienburg</city>
        <zip>31582</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wagener &amp; Hein, Nienburg, DE /ID# 218896</name>
      <address>
        <city>Nienburg</city>
        <zip>31582</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Klinik Bigge /ID# 218425</name>
      <address>
        <city>Olsberg</city>
        <zip>59939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Welcker, Planegg, DE /ID# 218543</name>
      <address>
        <city>Planegg</city>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Knappschaftsklinikum Saar GmbH /ID# 218901</name>
      <address>
        <city>Puettlingen</city>
        <zip>66346</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ratingen /ID# 218897</name>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Gemeinschaftspraxis Schwerin /ID# 218432</name>
      <address>
        <city>Schwerin</city>
        <zip>19053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melzer, Seesen, DE /ID# 220803</name>
      <address>
        <city>Seesen</city>
        <zip>38723</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Schwerpunktpr /ID# 218415</name>
      <address>
        <city>Stuttgart</city>
        <zip>70372</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumathologie Ulm /ID# 218539</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Josef /ID# 221392</name>
      <address>
        <city>Wuppertal</city>
        <zip>42105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Barmen /ID# 218895</name>
      <address>
        <city>Wuppertal</city>
        <zip>42285</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fricke-Wagner, Zwickau, DE /ID# 218533</name>
      <address>
        <city>Zwickau</city>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis (RA)</keyword>
  <keyword>Upadacitinib</keyword>
  <keyword>RINVOQ</keyword>
  <keyword>Methotrexate (MTX)</keyword>
  <keyword>ABT-494</keyword>
  <keyword>C-reactive protein (CRP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

